(Q35627818)

9 August 2017

1 reference

title

Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

9 August 2017

main subject

1 reference

based on heuristic

inferred from title

author

Katherine A Lyseng-Williamson

series ordinal

1

object named as

Katherine A Lyseng-Williamson

1 reference

9 August 2017

2

Gillian M Keating

1 reference

9 August 2017

publication date

1 January 2002

1 reference

Treatments in Respiratory Medicine

9 August 2017

published in

1 reference

9 August 2017

volume

1

1 reference

9 August 2017

issue

4

1 reference

9 August 2017

page(s)

273-82; discussion 283-4

1 reference

Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Should inhaled corticosteroids be used in the long term treatment of chronic obstructive pulmonary disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Salmeterol/fluticasone propionate combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta2-agonists and corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Salmeterol inhibits the allergen-induced mononuclear cell proliferation and downregulates GM-CSF release and HLA-DR expression by monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Nasal mucociliary clearance and salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Effect of salmeterol on human nasal epithelial cell ciliary beating: inhibition of the ciliotoxin, pyocyanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

The duration of action of non-beta 2-adrenoceptor mediated responses to salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Development of fluticasone propionate and comparison with other inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Safety of inhaled and intranasal corticosteroids: lessons for the new millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256618

21 January 2018

Identifiers

DOI

10.1007/BF03256618

1 reference

9 August 2017

1 reference